Anticoagulation management and poor clinical outcomes in tamariki and rangatahi with rheumatic heart disease following mechanical valve replacement surgery in Counties Manukau.

AIM: Rheumatic heart disease (RHD) causes significant cardiovascular morbidity and mortality, with persisting inequitably high rates in Māori and Pacific tamariki and rangatahi. Mechanical valve replacement surgery is required for people with severe RHD and requires lifetime anticoagulation. Contemporary data regarding anticoagulation management and outcomes for tamariki and rangatahi following mechanical valve replacement surgery for RHD are lacking. We aimed to describe patient characteristics, anticoagulation management practices and complications in a cohort of tamariki and rangatahi ≤25 years of age. METHODS: A retrospective observational study of patients aged ≤25 years with RHD and mechanical valves, living in Counties Manukau, South Auckland, 2016-2021, was conducted. RESULTS: A total of 53 patients were identified. The median age at time of first mechanical valve surgery was 15 years (range 4-23 years). Nineteen percent of the cohort were Māori and 81% were Pacific peoples. The median duration of anticoagulation was 4 years (range 0.5-18 years). The most common method of monitoring was via the community laboratory service and general practitioner. There were 38 individuals who had ≥1 anticoagulation-related hospitalisation. There were 80 anticoagulation-related hospitalisations: 52% were due to a subtherapeutic international normalised ratio (INR) without clinical complication; 15% had a supratherapeutic INR without clinical complication; 14% haemorrhage; 9% stroke; 6% other thromboembolic events; and 4% prosthetic valve thrombosis. Five deaths occurred between 2016 and 2021. CONCLUSION: The majority of the cohort had serious anticoagulation-related hospitalisation events, and 10% died. Urgent efforts are required to improve services for anticoagulation monitoring and management and clinical outcomes in young adults following mechanical valve surgery for RHD.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Rheumatic heart disease (RHD) causes significant cardiovascular morbidity and mortality, with persisting inequitably high rates in Māori and Pacific tamariki and rangatahi. Mechanical valve replacement surgery is required for people with severe RHD and requires lifetime anticoagulation.

Explore how this research connects to clinical practice

More peer-reviewed studies in Clinical Trials.

• Leech Therapy for Knee Osteoarthritis — The Landmark RCT — Michalsen et al. (2003)
• Leech-Assisted Flap Salvage — Systematic Review of 277 Cases — Whitaker et al. (2012)
• Effects of hirudotherapy on liver functions, lipid profile, and insulin sensitivity in rats with metabolic syndrome — Bilden A et al. (2026)
• Efficacy and Safety of Hirudotherapy for Improving Sperm Quality Parameters in Male Infertility: A Randomized Controlled Trial — Abtahi-Forooshani M et al. (2026)
• Reverse Sural Flap Venous Congestion Successfully Managed With Enoxaparin in a Male Patient With a Traumatic Foot Crush Injury: A Case Report — Velasco-Bustamante J et al. (2026)
• Investigation of the therapeutic effects of medicinal leech treatment on lower extremity ischemia-reperfusion injury — Ünal K et al. (2026)
• Efficacy of Medicinal Leech Therapy in Diverse Clinical Applications: A Comprehensive Study from Azerbaijan — Farzali S et al. (2025)
• HIRUDOTHERAPY IN RECONSTRUCTIVE SURGERY: CASE-REPORTS AND REVIEW — Heinz P et al. (2020)
• Hirudotherapy Efficacy and Complications in the Management of Microsurgical Breast Reconstruction: A Systematic Review — Foppiani J et al. (2024)
• Hirudotherapy in Wound Healing — Nair H et al. (2022)

Browse all ASH-analysed research →